摘要
目的检测原发性上皮性卵巢癌组织中ｃｅｒｂＢ２基因扩增，以探讨其在卵巢癌临床诊治中的价值。方法采用Ｓｏｕｔｈｅｒｎ印迹技术，结合特异性ｃｅｒｂＢ２探针，对１０８例原发性上皮性卵巢癌及３４例良性、７例交界性卵巢肿瘤手术切除组织做ＤＮＡ扩增。结果原发性上皮性卵巢癌ｃｅｒｂＢ２基因扩增频率为３２．４％（３５／１０８），而良性、交界性卵巢肿瘤均未出现扩增（Ｐ＜０．００１），且ｃｅｒｂＢ２基因的扩增和上皮性卵巢癌的ＦＩＧＯ分期（Ｐ＝０．０２５）、肿瘤细胞分化程度（Ｐ＝０．０１１）及初次手术后残存肿瘤的大小（Ｐ＜０．００１）呈正相关。经对８４例ＩＩ～ＩＶ期原发性上皮性卵巢癌进行预后分析，结果表明，ｃｅｒｂＢ２基因扩增为影响预后的独立因素，ｃｅｒｂＢ２基因扩增阴性者３年生存率为５７．７％，而阳性者为２８．４％，两者差异具有显著性（Ｐ＝０．０１６）。结论ｃｅｒｂＢ２基因扩增可能和原发性上皮性卵巢癌的发生有关，ｃｅｒｂＢ２基因扩增阳性患者恶性程度高，手术成功率低，预后明显差于阴性患者。检测癌组织中ｃｅｒｂＢ２基因的扩增，将有助于对卵巢癌患者的病情监测和预后判断。
Objective To study c erbB2 gene amplification in human primary epithelial ovarian cancer and its clinical significance. Methods One hundred forty nine samples of primary epithelial ovarian tumors, including 34 beign tumors,7 borderline tumors and 108 carcinoma, were studied for c erbB2 gene amplification by Southern blot analysis. Results c erbB2 gene amplification was detected in 35 (32.4%) of the 108 cases with primaey epithelial ovarian carcinoma, while all cases with beign tumors and borderline lesions were negative ( P <0.001). There was a strong correlation between c erbB2 gene amplification and FIGO stage of human ovarian carcinoma ( P =0.026), degree of cell differentiation ( P =0.011) and the size of residual tumor ( P <0.001). Univariate and multivariate analysis showed that c erbB2 gene amplification was an independent prognostic factor. The average 3 year survival rate was 28.4% in patients with gene amplification and 57.7% in patients without gene amplification( P =0.016). Conclusion c erbB2 gene amplification occurs almost in 1/3 of the patients with ovarian carcinoma examined. Ovarian carcinoma with c erbB2 gene amplification is highly malignant and associated with poor prognosis.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1998年第5期367-370,共4页
Chinese Journal of Oncology
基金
上海市科委基金及卫生部科学基金
